Aroa Biosurgery (ASX:ARX) YoY EPS Growth: 1,121.43% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ARX Aroa Biosurgery Ltd ASX:ARX
57 GF Score
Price A$0.53
GF Value A$0.88
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery YoY EPS Growth?

Aroa Biosurgery ASX:ARX +0.96% 57 YoY EPS Growth is 1,121.43% as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 57/100 and a GF Value™ of A$0.88 (Significantly Undervalued). The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Aroa Biosurgery's YoY EPS Growth for the quarter that ended in Mar. 2026 was 1,121.43%.

Aroa Biosurgery's Earnings per Share (Diluted) for the six months ended in Mar. 2026 was A$0.01.

Aroa Biosurgery YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery YoY EPS Growth Chart

Aroa Biosurgery Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only 61.31 95.67 -2,770.00 64.81 212.87

Aroa Biosurgery Semi-Annual Data
Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.76 48.82 88.03 59.77 1,121.43
ASX:ARX
57GF Score
Aroa Biosurgery Ltd ASX:ARX
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Aroa Biosurgery's YoY EPS Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EPS Growth (A: Mar. 2026 )
=(Earnings per Share (Diluted) (A: Mar. 2026 )-Earnings per Share (Diluted) (A: Mar. 2025 ))/ | Earnings per Share (Diluted) (A: Mar. 2025 ) |
=(0.0114--0.0101)/ | -0.0101 |
=212.87 %

Aroa Biosurgery's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(0.0143--0.0014)/ | -0.0014 |
=1,121.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 1,121.43% mean?
Aroa Biosurgery (ASX:ARX) has a YoY EPS Growth of 1,121.43% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's YoY EPS Growth too high?
Aroa Biosurgery's current YoY EPS Growth is 1,121.43%. Overall, Aroa Biosurgery has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's YoY EPS Growth compare to ABT and SYK?
Aroa Biosurgery's YoY EPS Growth of 1,121.43% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Aroa Biosurgery and its competitors. Aroa Biosurgery's current YoY EPS Growth is 1,121.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.88, compared to a current price of A$0.53 — trading 40.3% below its estimated fair value. The current YoY EPS Growth is 1,121.43%. Aroa Biosurgery's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current YoY EPS Growth is 1,121.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.53 is trading 40.3% below its estimated GF Value™ of A$0.88. GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.

Key valuation signals for ASX:ARX:

  • YoY EPS Growth: 1,121.43%
  • GF Value™: A$0.88 vs. price of A$0.53 (40.3% below fair value)
  • GF Score™: 57/100 with 1 warning sign

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a New Zealand-based medical device company that develops, manufactures, and sells soft tissue regeneration products based on its proprietary extracellular matrix (ECM) technology, derived from ovine forestomach tissue. Its products, marketed under the Endoform and Myriad brands, are used in wound care and soft tissue reconstruction, targeting applications such as chronic wounds, hernia repair, plastic and reconstructive surgery, trauma, limb salvage, and tumor surgery. The company's primary market is the United States, where it sells through a direct sales force and partnerships with distributors and wound care providers, with additional sales in other international markets. Aroa generates revenue mainly from product sales to hospitals, clinics, and healthcare distributors, and also pursues licensing and collaboration arrangements. It operates manufacturing and research facilities in New Zealand.
57GF Score

Get the complete analysis for ASX:ARX

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.53
Price
A$0.88
GF Value